A5013497028- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Cancer Risks and Factors
- BRCA gene mutations in cancer
- Breast Lesions and Carcinomas
- Glioma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Cancer, Lipids, and Metabolism
- Market Dynamics and Volatility
- Gut microbiota and health
- Cancer Diagnosis and Treatment
- Estrogen and related hormone effects
- Colorectal Cancer Screening and Detection
University of Padua
2017-2025
Istituto Oncologico Veneto
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
University of Bari Aldo Moro
2022-2024
Azienda Ospedaliera S.Giuseppe Moscati
2024
UniCredit (Italy)
2023
Burning Rock Biotech (China)
2019
Inserm
2018
Université de Montpellier
2018
Institut de Recherche en Cancérologie de Montpellier
2018
Abstract About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim this study is to describe the evolution HER2 from primary BC relapse including category in both and recurrent samples. Patients with matched samples were included. was evaluated according ASCO/CAP recommendations place at time diagnosis. A cutoff >10% cells staining for HER2-positivity applied. cases sub-classified as (IHC = 1 + /2+ ISH not...
Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described high instability expression from primary cancer (BC) to relapse. Previous studies reporting discordance in HER2 status between baseline biopsy and residual disease (RD) patients undergoing neoadjuvant treatment did not include the category. The aim this study is track evolution BC RD after treatment. Patients with available tumor tissue matched samples (in case no...
Hormone receptor-positive/HER2-negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR) rare multiple efforts have been made to predict disease recurrence. We developed a framework pCR using clinicopathological characteristics widely available at diagnosis. The machine learning (ML) models were trained (n = 463), evaluated in internal validation...
BackgroundThere is the need to identify new prognostic markers refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was evaluate association tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients enrolled ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab addition chemotherapy, and test interaction between TILs treatment arm.Patients methodsStromal were assessed 866 cases on centralized...
Tumor-infiltrating lymphocytes (TILs) evaluated in primary breast cancer (BC) convey prognostic information. Limited data the metastatic setting are available. Secondary lesions from 94 BC patients, 43 triple-negative (TN) and 51 HER2-positive, were for TILs expression of CD8, FOXP3, PD-L1 by immunohistochemistry. levels on metastasis generally low (median 5%) did not differ between TN HER2+ tumors. Younger patients showed significantly lower (p = 0.002). In higher lung metastases as...
Background. We evaluated immunohistochemical AR expression and correlation with prognosis in a large series of homogeneously treated patients primary TNBC. Material methods. Patients diagnosed stage I-III TNBC between 2000 2015 at Istituto Oncologico Veneto who received treatment surgery neoadjuvant and/or adjuvant chemotherapy were included. Whole tissue slides stained for AR. AR-positive was defined as >1% positively tumor cells. Distant-disease-free survival (DDFS) calculated from...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned coprimary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We present final analysis of phase III noninferiority, randomized ShortHER comparing 9 weeks versus 1 year adjuvant...
Tumour infiltrating lymphocytes (TILs) are an established prognostic biomarker for triple-negative breast cancer (TNBC). We evaluated the role of programmed cell-death ligand-1 (PD-L1), CD8 and FOXP3 expression in refining a model non-metastatic TNBC beyond classic factors TILs.Primary tumour samples from 244 early patients with TNBC, all treated surgery chemotherapy, were collected. Stromal TILs on haematoxylin-eosin slides according to guidelines. PD-L1, assessed by immunohistochemistry...
Immunotherapy has revolutionized cancer therapy and now represents a standard of care for many tumor types, including triple-negative breast cancer. Despite the positive results that have led to approval immunotherapy in both early- advanced-stage cancer, pivotal clinical trials cannot address myriad questions arising everyday practice, often falling short delivering all information clinicians require. In this manuscript, we aim some these practical questions, with purpose providing guide...
Importance For patients with early ERBB2 (formerly HER2 )–positive breast cancer, there is a need to identify biomarkers guide treatment de-escalation. Objective To evaluate the association of tumor-infiltrating lymphocytes (TILs) distant disease-free (DDFS) and overall survival (OS) for -positive cancer. Design, Setting, Participants The ShortHER randomized clinical trial was multicentric in Italy that enrolled cancer from December 2007 October 2013. Patients received 9 weeks or 1 year...
Interest in metastatic solid tumors patients achieving exceptionally durable responses to systemic treatment is progressively increasing; however, available evidence still remains limited. This study characterizes with breast cancer (mBC) an exceptional response, a focus on discontinuing treatment. In this retrospective monocentric study, mBC (2021-2023) were identified; clinical features, hormone receptor (HR) and HER2 status, radiological collected. Exceptional response was defined as...